SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    S. K. Amugongo, W. Yao, J. Jia, Y.-A. E. Lay, W. Dai, L. Jiang, D. Walsh, C.-S. Li, N. K. N. Dave, D. Olivera, B. Panganiban, R. O. Ritchie, N. E. Lane, Effects of sequential osteoporosis treatments on trabecular bone in adult rats with low bone mass, Osteoporosis International, 2014, 25, 6, 1735

    CrossRef

  2. 2
    K. Khan, K. Sharan, G. Swarnkar, B. Chakravarti, M. Mittal, T. K. Barbhuyan, S. P. China, M. P. Khan, G. K. Nagar, D. Yadav, P. Dixit, R. Maurya, N. Chattopadhyay, Positive skeletal effects of cladrin, a naturally occurring dimethoxydaidzein, in osteopenic rats that were maintained after treatment discontinuation, Osteoporosis International, 2013, 24, 4, 1455

    CrossRef

  3. 3
    Yakir Anavi, Gal Avishai, Shlomo Calderon, Dror M Allon, Bone Remodeling in Onlay Beta-Tricalcium Phosphate and Coral Grafts to Rat Calvaria: Microcomputerized Tomography Analysis, Journal of Oral Implantology, 2011, 37, 4, 379

    CrossRef

  4. 4
    E. Lespessailles, C. Jaffré, H. Beaupied, P. Nanyan, E. Dolléans, C. L. Benhamou, D. Courteix, Does Exercise Modify the Effects of Zoledronic Acid on Bone Mass, Microarchitecture, Biomechanics, and Turnover in Ovariectomized Rats?, Calcified Tissue International, 2009, 85, 2, 146

    CrossRef

  5. 5
    Z.-F. Sheng, K. Xu, Y.-L. Ma, J.-H. Liu, R.-C. Dai, Y.-H. Zhang, Y.-B. Jiang, E.-Y. Liao, Zoledronate reverses mandibular bone loss in osteoprotegerin-deficient mice, Osteoporosis International, 2009, 20, 1, 151

    CrossRef

  6. 6
    Audrey Neuprez, Jean-Yves Reginster, Bone-forming agents in the management of osteoporosis, Best Practice & Research Clinical Endocrinology & Metabolism, 2008, 22, 5, 869

    CrossRef

  7. 7
    M. G. Sørensen, K. Henriksen, S. Schaller, M. A. Karsdal, Biochemical markers in preclinical models of osteoporosis, Biomarkers, 2007, 12, 3, 266

    CrossRef

  8. 8
    Wei Yao, Ming Su, Qing Zhang, Xiaoyan Tian, Rebecca B. Setterberg, Cindy Blanton, Mark W. Lundy, Roger Phipps, Webster S.S. Jee, Risedronate did not block the maximal anabolic effect of PTH in aged rats, Bone, 2007, 41, 5, 813

    CrossRef

  9. 9
    Takahiro Hashimoto, Mitsunori Shigetomi, Teruyasu Ohno, Tsunemitsu Matsunaga, Keiichi Muramatsu, Hiroshi Tanaka, Toshihiro Sugiyama, Toshihiko Taguchi, Sequential Treatment with Intermittent Low-Dose Human Parathyroid Hormone (1-34) and Bisphosphonate Enhances Large-Size Skeletal Reconstruction by Vascularized Bone Transplantation, Calcified Tissue International, 2007, 81, 3, 232

    CrossRef

  10. 10
    Yumie Rhee, Jong Chan Youn, Ye-Yeon Won, Myong-Hyun Baek, Sung-Kil Lim, Effect of Sequential Therapy with Incadronate after Withdrawal of Recombinant Human Parathyroid Hormone (1-84) on Bone Quantity and Quality in Ovariectomized Rats, Journal of Korean Society of Endocrinology, 2005, 20, 4, 334

    CrossRef

  11. 11
    S. Schaller, K. Henriksen, P. Hoegh-Andersen, B.C. Søndergaard, E.U. Sumer, L.B. Tanko, P. Qvist, M.A. Karsdal, In Vitro, Ex Vivo, andIn VivoMethodological Approaches for Studying Therapeutic Targets of Osteoporosis and Degenerative Joint Diseases: How Biomarkers Can Assist?, ASSAY and Drug Development Technologies, 2005, 3, 5, 553

    CrossRef

  12. 12
    Ki-Hyun Baek, Sequential and Combination Therapy using Parathyroid Hormone for Osteoporosis, Journal of Korean Society of Endocrinology, 2005, 20, 4, 319

    CrossRef

  13. 13
    Ego Seeman, Gordon J Strewler, Clinical and Basic Research Papers – July 2004 Selections, BoneKEy-Osteovision, 2004, 1, 9, 1

    CrossRef

  14. 14
    Marie-Paul Lecart, Olivier Bruyere, Jean-Yves Reginster, Combination/sequential therapy in osteoporosis, Current Osteoporosis Reports, 2004, 2, 4, 123

    CrossRef

  15. 15
    Marie-Paul Lecart, Olivier Bruyere, Jean-Yves Reginster, Combination/sequential therapy in osteoporosis, Current Osteoporosis Reports, 2004, 2, 4, 123

    CrossRef